Watson Pharma (WPI) Confirms Patent Challenge on Epiduo Gel

Article Stock Quotes (1) Comments (0)

Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. FDA seeking approval to market Epiduo® (adapalene and benzoyl peroxide) Gel, 0.1% / 2.5%. Watson's ANDA product is a generic version of Galderma Laboratories, L.P. Epiduo® Gel is a topical ointment prescription drug that combines a retinoid (adapalene) and an antimicrobial (benzoyl peroxide) for the treatment of acne vulgaris (severe acne) in people who are at least 12 years old.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Orchard Supply (OSH) Receives Approval of All First Day Motions
• Tesla (TSLA) Announces Partial Model S Recall
• Actavis (ACT), Kissei Pharma Sue Sandoz, Hetero Over Rapaflo Patent

Create E-mail Alert Related Categories

Corporate News, Litigation

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?